Pfizer
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines and vaccines for a wide range of therapeutic areas including oncology, immunology, cardiology, and infectious diseases. It serves patients, healthcare providers, governments, and health systems worldwide, generating revenue primarily through the sale of patented and off-patent drugs and vaccines. The company also engages in research collaborations and licensing agreements with other biopharma and biotech firms.
- Revenue
- $58.5B
- Employees
- 83,000
- Founded
- 1849
- Headquarters
- New York City, United States of America
What 10 Arbolus experts think of Pfizer
NPS feedback is predominantly positive, with the majority of scores ranging between 6 and 10, primarily driven by executive and clinical Users citing scale, R&D strength, and distribution reliability as key value drivers. Renewal intent among Influencers is generally favorable, though select Influencers report offboarding or uncertain renewal, often tied to pricing and market competition. Most experts are in the advanced implementation or pilot stages, reflecting ongoing institutional engagements and product evaluations. Main qualitative themes include recognition of Pfizer's large-scale infrastructure, scientific leadership, product availability, and concerns over complexity and cost.Overall Customer Sentiment: Positive
Who reviewed Pfizer
- C-Suite 56% (6)
- Director 11% (1)
- Manager 33% (3)
Employer names and spend open in the full report, along with the other 7 customers.
Everything 10 customers told us about Pfizer.
Employer names, spend, renewal intent and every written answer behind the numbers on this page.
Sentiment
10 Net Promoter Score, from 10 scored reviews- Promoters 3
- Passives 5
- Detractors 2
Cumulative NPS by month
+0 over 5 months- Jun 8
- Jan 8
- Mar 8
- Jul 8
- Sep 8
Net Promoter Score across 1 reviews, accumulated up to each month. Category median 10 across 1 companies.
Praised
- Global Scale and Reach
- Supply-Chain Reliability
- R&D Investment and Innovation
- Digital Patient Support
Criticised
- Portfolio and Patent-Expiration Risk
- Competitive Therapy Threats
- Pricing and Market Access Pressure
- Internal Complexity
What customers say
Renewal intent
Plan to renew 50%Plan to renew, by seniority
- 100% 2 answers
- 0% 1 answer
- 0% 1 answer
- 8/10 Average score from customers who will renew
- 6/10 Average score from undecided customers
- 8/10 Average score from customers not renewing
Report
For people who use Pfizer
Do you use Pfizer at work?
Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.
- 10 customers of Pfizer have already contributed
Takes a few minutes. Your identity stays anonymous.